Skip Nav Destination
Issues
1 April 2024
-
Cover Image
Cover Image
The cover image is adapted from Fig. 2 in the article, “Oncogenic Oral Human Papillomavirus Clearance Patterns Over 10 Years,” by D'Souza and colleagues. Effective screening for oropharyngeal cancer (OPC) is lacking. To understand risk factors for progression to HPV-related oropharyngeal cancer (HPV-OPC), defining HPV clearance is key. This study explored oncogenic oral HPV clearance, the inverse of “persistence” which is necessary for development of HPV-OPC. Prospective multicenter cohort of participants living with/at-risk for HIV, with oral rinse and gargle samples collected every 6 to 12 months for up to 10 years and tested for oral HPV, the precursor of OPC. Four oncogenic HPV clearance definitions were explored to understand long-term natural history for persistent oncogenic oral HPV. HPV clearance definitions included 1 (clear1), 2 (clear2), 3 (clear3) consecutive negatives, or being negative at last two visits (clearlast). Figure 2 shows the clearance of prevalent and incident oncogenic oral HPV infections over 10 years. Detection of prevalent oncogenic oral HPV, older age, male sex, and living with HIV were independently associated with reduced clearance. Stringent clearance definitions requiring ≥2 negatives better captured individuals at-risk for HPV-OPC. Men with prevalent HPV16 and ≥2 consecutive HPV16 detections identified long-term persisters at increased risk for OPC, implying a potential for a targeted screening approach. For more information, see the article beginning on page 516. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1055-9965
EISSN 1538-7755
Highlights
Commentary
In the Spotlight
Reviews
Research Articles
Interaction between Continuous Pack-Years Smoked and Polygenic Risk Score on Lung Cancer Risk: Prospective Results from the Framingham Heart Study
Meredith S. Duncan; Hector Diaz-Zabala; James Jaworski; Hilary A. Tindle; Robert A. Greevy; Loren Lipworth; Rayjean J. Hung; Matthew S. Freiberg; Melinda C. Aldrich
Unveiling an Association between Waterpipe Smoking and Bladder Cancer Risk: A Multicenter Case–Control Study in Iran
Maryam Hadji; Hamideh Rashidian; Maryam Marzban; Abbas Rezaianzadeh; Alireza Ansari-Moghaddam; Mahdieh Bakhshi; Azim Nejatizadeh; Monireh Sadat Seyyedsalehi; Ahmad Naghibzadeh-Tahami; AliAkbar Haghdoost; Elham Mohebbi; Neal D. Freedman; Reza Malekzadeh; Arash Etemadi; Farin Kamangar; Elisabete Weiderpass; Eero Pukkala; Paolo Boffetta; Kazem Zendehdel
Oncogenic Oral Human Papillomavirus Clearance Patterns over 10 Years
Gypsyamber D'Souza; Sakshi R. Tewari; Tanya Troy; Jennifer Webster-Cyriaque; Dorothy J. Wiley; Cecile Delille Lahiri; Frank Joseph Palella; Maura L. Gillison; Howard D. Strickler; Linda Struijk; Tim Waterboer; Ken Ho; Jennafer Kwait; Jason Lazar; Kathleen M. Weber; Carole Fakhry
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature
Claire E. Thomas; Peter Georgeson; Conghui Qu; Robert S. Steinfelder; Daniel D. Buchanan; Mingyang Song; Tabitha A. Harrison; Caroline Y. Um; Meredith A. Hullar; Mark A. Jenkins; Bethany Van Guelpen; Brigid M. Lynch; Yohannes Adama Melaku; Jeroen R. Huyghe; Elom K. Aglago; Sonja I. Berndt; Lisa A. Boardman; Peter T. Campbell; Yin Cao; Andrew T. Chan; David A. Drew; Jane C. Figueiredo; Amy J. French; Marios Giannakis; Ellen L. Goode; Stephen B. Gruber; Andrea Gsur; Marc J. Gunter; Michael Hoffmeister; Li Hsu; Wen-Yi Huang; Victor Moreno; Neil Murphy; Polly A. Newcomb; Christina C. Newton; Jonathan A. Nowak; Mireia Obón-Santacana; Shuji Ogino; Wei Sun; Amanda E. Toland; Quang M. Trinh; Tomotaka Ugai; Syed H. Zaidi; Ulrike Peters; Amanda I. Phipps
The Impact of Inherited Genetic Variation on DNA Methylation in Prostate Cancer and Benign Tissues of African American and European American Men
Dayana Delgado; Marc Gillard; Lin Tong; Kathryn Demanelis; Meritxell Oliva; Kevin J. Gleason; Meytal Chernoff; Lin Chen; Gladell P. Paner; Donald Vander Griend; Brandon L. Pierce
Null Results in Brief
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.